ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

Health Care Reform: Fundamental changes Ahead For Cancer Research And Care

October 8, 1993

Niederhuber Leads AACI

November 2, 2001

FDA News: Clinton Nominates Jane Henney For FDA Commissioner

June 26, 1998

ACS-Roosevelt Fellows Announced

July 29, 1977

Nexavar Improves PFS In HER-2 Negative Breast Cancer

May 27, 2011

National Cancer Act Creates Expectation Of Independence, Leads To Conflict With NIH, Broder Says

January 20, 1995